EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia

Melvin H Seid iD, Angelia D Butcher, Ashwin Chatwani

Anemia · 2017 · 2017 · 1-9

DOI: 10.1155/2017/9642027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anemia, 2017. Verfasst von Melvin H Seid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unified Women's Clinical Research, 1100-C South Stratford Road, Suite 310, Winston-Salem, NC 27103, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Luitpold Pharmaceuticals.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate safety and efficacy of intravenous ferric carboxymaltose (FCM) versus standard medical care (SMC) for iron-deficiency anemia (IDA) in postpartum women and women with heavy menstrual bleeding. Study Design . This open-label, multicenter study randomized women with IDA (hemoglobin ≤ 11.0 g/dL) to single doses of FCM (15 mg/kg [maximum 1000 mg]) or SMC (this treatment was determined by the investigator and there may have been no treatment). Safety data (primary outcome) were collected for 30 days.

Results

Of 2045 subjects enrolled (FCM: n = 1023 ; SMC: n = 1022 ), 996 received FCM and 1022 received SMC. At least 1 serious adverse event (AE) was reported by 0.6% and 2.2% of subjects in the FCM and SMC groups, respectively; none were considered treatment related. The difference in serious AEs was primarily due to higher rates of uterine leiomyoma, uterine hemorrhage, and menorrhagia in SMC subjects with heavy menstrual bleeding. Common AEs were generally predictable, with higher rates of infusion site reactions in FCM subjects and gastrointestinal AEs in SMC subjects. Mean hemoglobin increases were greater in the FCM group than the SMC group.

Conclusion

FCM was well tolerated and effectively increased mean hemoglobin levels in postpartum women or women with heavy menstrual bleeding and IDA. This trial is registered with ClinicalTrials.gov, NCT00548860 .

Autor:innen und Institutionen

  • Unified Women's Clinical Research, 1100-C South Stratford Road, Suite 310, Winston-Salem, NC 27103, USA.
  • Luitpold Pharmaceuticals, Inc., 800 Adams Ave, Suite 100, Norrisville, PA 19403, USA.
  • Department of Obstetrics and Gynecology, Temple University School of Medicine, Philadelphia, PA 19140, USA.

ORCID-Profile: Melvin H Seid

Förderung

  • Luitpold Pharmaceuticals

Zitieren

APA

Seid, M. H., Butcher, A. D., & Chatwani, A. (2017). Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia, 2017, 1-9. https://doi.org/10.1155/2017/9642027

Vancouver

Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017;2017:1-9. doi:10.1155/2017/9642027

BibTeX
@article{Seid2017,
  author = {Seid, Melvin H and Butcher, Angelia D and Chatwani, Ashwin},
  title = {Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia},
  journal = {Anemia},
  year = {2017},
  volume = {2017},
  pages = {1--9},
  doi = {10.1155/2017/9642027}
}
Kostenlos starten →